Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease.
- 1Clinica Medica, Department of Medicine, University of Udine, Udine, Italy.
Abstract
Epidemiological evidence demonstrates that atherosclerotic cardiovascular disease (ASCVD) is a major cause of death and disability in patients with chronic kidney disease (CKD). From the early stages of CKD, and in addition to specifically related conditions, the coexistence of traditional risk factors contributes to a process of accelerated atherosclerosis. In patients with CKD, increased cardiovascular risk persists even after correction of hypertension, dyslipidemia, and diabetes, indicating a residual risk likely related to additional subtle factors. Lipoprotein(a) [Lp(a)] is an LDL-like particle containing apoB100 covalently linked to apo(a) and is now recognized as a genetically determined risk factor for ASCVD. Following its initial description, Lp(a) aroused extraordinary interest, which then waned in the late-1990s due to the controversial results of some prospective studies and the lack of effective interventions to reduce its circulating levels. Over the past two decades, clinical studies have provided robust evidence supporting the causal and independent contribution of Lp(a) to ASCVD, also suggesting a significant contribution to residual cardiovascular risk. This contribution may be particularly significant in patients with CKD, who exhibit elevated Lp(a) levels from the earliest stages of disease. The recent development of potent Lp(a)-lowering drugs offers an exciting opportunity to effectively address residual risk in the general population and in patients with CKD. No data are yet available on their use in patients with CKD but pending future definition of their efficacy on cardiovascular outcomes, approval, dosing, and long-term safety, these drugs might possibly represent a useful tool for cardiovascular prevention in these patients.
Related
- Cumulative non-high-density lipoprotein cholesterol exposure and residual cardiovascular mortality risk in patients with peripheral artery disease.
- Elevated lipoprotein (a) and large apo(a) isoforms in Omani patients: a distinct cardiovascular risk profile
- Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
- Lipoprotein(a) and adverse cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis.
- Combined Triglyceride–High-density Lipoprotein Cholesterol Phenotypes and Cardiovascular Outcomes in Japanese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights from Clinical Deep Data Accumulation System-PCI
BibTeX
@article{sechi2026lipoproteina,
title = {{Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease.}},
author = {Leonardo A Sechi and Luca Bulfone and Antonio Vacca and Jacopo Comand and Stefano Marcante and Gabriele Brosolo and Claudio Pagano and Cristiana Catena},
journal = {Frontiers in nephrology},
year = {2026},
month = oct,
doi = {10.3389/fneph.2026.1950030},
url = {https://europepmc.org/article/MED/42909215},
note = {CC BY},
}
RIS
TY - JOUR
TI - Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease.
AU - Leonardo A Sechi
AU - Luca Bulfone
AU - Antonio Vacca
AU - Jacopo Comand
AU - Stefano Marcante
AU - Gabriele Brosolo
AU - Claudio Pagano
AU - Cristiana Catena
PY - 2026
DA - 2026/10/07
JO - Frontiers in nephrology
DO - 10.3389/fneph.2026.1950030
UR - https://europepmc.org/article/MED/42909215
AB - Epidemiological evidence demonstrates that atherosclerotic cardiovascular disease (ASCVD) is a major cause of death and disability in patients with chronic kidney disease (CKD). From the early stages of CKD, and in addition to specifically related conditions, the coexistence of traditional risk factors contributes to a process of accelerated atherosclerosis. In patients with CKD, increased cardiovascular risk persists even after correction of hypertension, dyslipidemia, and diabetes, indicating a residual risk likely related to additional subtle factors. Lipoprotein(a) [Lp(a)] is an LDL-like particle containing apoB100 covalently linked to apo(a) and is now recognized as a genetically determined risk factor for ASCVD. Following its initial description, Lp(a) aroused extraordinary interest, which then waned in the late-1990s due to the controversial results of some prospective studies and the lack of effective interventions to reduce its circulating levels. Over the past two decades, clinical studies have provided robust evidence supporting the causal and independent contribution of Lp(a) to ASCVD, also suggesting a significant contribution to residual cardiovascular risk. This contribution may be particularly significant in patients with CKD, who exhibit elevated Lp(a) levels from the earliest stages of disease. The recent development of potent Lp(a)-lowering drugs offers an exciting opportunity to effectively address residual risk in the general population and in patients with CKD. No data are yet available on their use in patients with CKD but pending future definition of their efficacy on cardiovascular outcomes, approval, dosing, and long-term safety, these drugs might possibly represent a useful tool for cardiovascular prevention in these patients.
SN - 2813-0626
ER -